Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-16
2007-01-16
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S375000, C435S377000, C536S023100, C536S024100
Reexamination Certificate
active
10156603
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6472521 (2002-10-01), Uhlmann et al.
patent: 2004/0009156 (2004-01-01), Reinhard et al.
Blangy et al.,Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo, Cell, 1995, 83:1159-1169.
Ferhat et al.,Expression of the mitotic motor protein Eg5 in postmitotic neurons: implications for neuronal development, J. Neurosci., 1998, 18:7822-7835.
Hansen et al.,Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia, Oncogene, 1999, 18:6531-6539.
Kaiser et al.,All-trans-retinoic acid-mediated growth inhibition involves inhibition of human kinesin-related protein HsEg5, J. Biol. Chem., 1999, 274:18925-18931.
Kapoor et al.,Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5, J. Cell Biol., 2000, 150:975-988.
Mayer et al.,Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen, Science, 1999, 286:971-974.
Miki et al.,All kinesin superfamily protein, KIF, genes in mouse and human, Proc. Natl. Acad. Sci. U. S. A., 2001, 98:7004-7011.
Whitehead et al.,Expanding the role of HsEg5 within the mitotic and post-mitotic phases of the cell cycle, J. Cell Sci., 1998, 111:2551-2561.
Whitehead et al.,The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus, Arthritis Rheum., 1996, 39:1635-1642.
Agrawal S., et al., “Antisense therapeutics: is it as simple as complementary base recognition?”Molecular Med. Today, 2000, 6, 72-81.
Branch, A.D., “A good antisense molecule is hard to find,”TIBS, 1998, 23, 45-50.
Jen, K.-Y., et al., “Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies,”Stem Cells, 2000, 18, 307-319.
Dobie Kenneth W.
Koller Erich
Isis Pharmaceuticals , Inc.
Knobbe Martens Olson and Bear LLP
McGarry Sean
LandOfFree
Antisense modulation of kinesin-like 1 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of kinesin-like 1 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of kinesin-like 1 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807940